Cancer cell-dependent increase in senescence-like populations following exosome treatment from bone marrow and induced pluripotent stem cell-derived mesenchymal stem cells

Figure 1 Characterization of induced pluripotent stem cell-derived mesenchymal stem cells and bone marrow mesenchymal stem cells. A: Flow cytometry analysis showed the expression of mesenchymal stem cell (MSC) positive surface markers (CD90, CD105, CD73, CD44) and negative hematopoietic lineage markers (CD34, CD45, CD14, CD11b, CD79a, CD19, HLA-DR) in both induced pluripotent stem cell-derived MSCs (iMSCs) and bone marrow MSCs (BMSCs); B: Quantitative comparison of human MSC surface marker expression between iMSCs and BMSCs; C: Osteogenic and adipogenic differentiation of iMSCs and BMSCs demonstrated by Alizarin Red staining (top panels) indicating calcium deposits and Oil Red O staining (bottom panels) showing lipid droplet formation. Images of differentiated iMSC-derived cells are displayed in the lower left panels while those of BMSC-derived cells appear in the lower right panels (scale bar = 50 μm). iMSCs: Induced pluripotent stem cell-derived mesenchymal stem cells; BMSCs: Bone marrow mesenchymal stem cell; MSCs: Mesenchymal stem cells.